Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687746 | 0.98 | L3MBTL1 (0.52) | L3MBTL1ATMTDP1PBRM1CYP19A1 | |
| SCHEMBL6471185 | 0.88 | PTGS1 (0.48) | L3MBTL1ATMTDP1CA1CA2 | |
| SCHEMBL29108703 | 0.85 | FOLH1 (0.54) | CA1CA2FOLH1 | |
| SCHEMBL29001417 | 0.85 | MEN1 (0.50) | L3MBTL1ATMTDP1STSCA1 | |
| SCHEMBL687745 | 0.84 | ATM (0.50) | L3MBTL1ATMTDP1PBRM1CYP19A1 | |
| SCHEMBL6454767 | 0.82 | L3MBTL1 (0.47) | L3MBTL1ATMTDP1PBRM1CYP19A1 | |
| SCHEMBL6454517 | 0.81 | CYP19A1 (0.36) | L3MBTL1ATMTDP1CYP19A1ALDH1A1 | |
| SCHEMBL4669025 | 0.80 | TDP1 (0.61) | L3MBTL1ATMTDP1PBRM1CYP19A1 | |
| SCHEMBL7394259 | 0.80 | TDP1 (0.61) | L3MBTL1ATMTDP1PBRM1CYP19A1 | |
| SCHEMBL13189361 | 0.79 | HPGD (0.48) | L3MBTL1ATMTDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | claimed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | claimed |
| CN-100372831-C | Sulfonic acids, derivatives thereof and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2008-03-05 | — | — | CN | claimed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | claimed |
| CN-1761645-A | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2006-04-19 | — | — | CN | claimed |
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| CN-100372831-C | Sulfonic acids, derivatives thereof and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2008-03-05 | — | — | CN | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
| CN-1761645-A | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2006-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | L3MBTL1 4272/4885ATM 3607/4885TDP1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.